Summary

Inosine Pranobex Market
The inosine pranobex market was valued at $217.0 million in 2023 and is projected to reach $271.5 million by 2033, growing at a CAGR of 2.3% from 2024 to 2033.
Inosine pranobex is a combination antiviral drug consisting of inosine, dimethylaminoisopropanol, and acetamidobenzoic acid. The drug improves the immune system of individuals by promoting the proliferation of T-cell lymphocytes and enhancing the activity of natural killer cells. It further boosts pro-inflammatory cytokines levels, reviving the deficient responses of immunosuppressed patients. Moreover, inosine pranobex significantly impacts the viral RNA levels, which impedes the growth of viruses.

Upsurge in the outbreak of different viral diseases has fueled the demand for ingenious treatment solutions, augmenting the growth of the inosine pranobex market. Furthermore, rise in the popularity of immunomodulatory therapies for the stimulation of immune system has increased the requirement for inosine pranobex owing to its excellent modification abilities. This acts as a key driver of the market. A notable trend gaining prominence in the market is the combination of inosine pranobex with other drugs or elements to form novel medications with enhanced efficacy and patient outcomes. Such combination medicines notably benefit patients with rare or resistant viral strains.

However, inosine pranobex faces stringent competition from alternative medications & antiviral drugs such as acyclovir and valganciclovir. This stringent competition considerably hampers the market growth. In addition, the drug exhibits the possibility to cause certain side effects in some individuals, ranging from gastrointestinal issues to severe allergic reactions, restraining the development of the inosine pranobex market. On the contrary, rise in the administration of inosine pranobex therapy in cancer patients is projected to open new avenues for the market owing to increase in the prevalence of different cancer forms. The 2024 Global Cancer Statistics by the American Cancer Society predicts the number of cancer cases across the globe to rise from 20 million in 2022 to approximately 35 million by 2050. This surge is projected to fuel the requirement for inosine pranobex therapy, presenting lucrative opportunities for the market.

Segment Review
The inosine pranobex market is segmented into type, application, distribution channel, and region. On the basis of type, the market is bifurcated into tablet and syrup. According to application, it is divided into immunomodulation, antiviral, and others. As per distribution channel, it is classified into hospitals pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of type, the tablet segment is expected to dominate the market during the forecast period.
According to application, the antiviral segment is projected to be the highest shareholder by 2033.
As per distribution channel, the drug stores & retail pharmacies segment is anticipated to acquire a high stake in the market throughout the forecast period.
Region wise, North America is predicted to be the highest revenue generator by 2033.
Competition Analysis
The major players in the global inosine pranobex market include Teva Pharmaceutical Industries Ltd., Newport Pharmaceuticals Ltd., Mylan N.V., Adamed Group S.A., Sanofi, Johnson & Johnson, Pfizer Inc., Novartis AG, Abbott Laboratories, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Additional company profiles with specific to client's interest
● Expanded list for Company Profiles
● Historic market data
Key Market Segments
By Type
● Tablet
● Syrup
By Application
● Immunomodulation
● Antiviral
● Others
By Distribution Channel
● Hospitals Pharmacies
● Drug Stores and Retail Pharmacies
● Online Providers
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ France
○ Germany
○ Italy
○ Spain
○ UK
○ Rest of Europe
● Asia-Pacific
○ China
○ Japan
○ India
○ South Korea
○ Australia
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ South Africa
○ Saudi Arabia
○ Rest of LAMEA
● Key Market Players
○ Teva Pharmaceutical Industries Ltd.
○ Newport Pharmaceuticals Ltd.
○ Mylan N.V.
○ Adamed Group S.A.
○ Sanofi
○ Johnson & Johnson
○ Pfizer Inc.
○ Novartis AG
○ Abbott Laboratories
○ Merck & Co., Inc.

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: INOSINE PRANOBEX MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Tablet
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Syrup
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: INOSINE PRANOBEX MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Immunomodulation
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Antiviral
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Others
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: INOSINE PRANOBEX MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospitals Pharmacies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Drug Stores And Retail Pharmacies
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Providers
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: INOSINE PRANOBEX MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Type
7.2.3. Market Size and Forecast, By Application
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Inosine Pranobex Market
7.2.6.1. Market Size and Forecast, By Type
7.2.6.2. Market Size and Forecast, By Application
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Inosine Pranobex Market
7.2.7.1. Market Size and Forecast, By Type
7.2.7.2. Market Size and Forecast, By Application
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Inosine Pranobex Market
7.2.8.1. Market Size and Forecast, By Type
7.2.8.2. Market Size and Forecast, By Application
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Type
7.3.3. Market Size and Forecast, By Application
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. France Inosine Pranobex Market
7.3.6.1. Market Size and Forecast, By Type
7.3.6.2. Market Size and Forecast, By Application
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. Germany Inosine Pranobex Market
7.3.7.1. Market Size and Forecast, By Type
7.3.7.2. Market Size and Forecast, By Application
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. Italy Inosine Pranobex Market
7.3.8.1. Market Size and Forecast, By Type
7.3.8.2. Market Size and Forecast, By Application
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Spain Inosine Pranobex Market
7.3.9.1. Market Size and Forecast, By Type
7.3.9.2. Market Size and Forecast, By Application
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. UK Inosine Pranobex Market
7.3.10.1. Market Size and Forecast, By Type
7.3.10.2. Market Size and Forecast, By Application
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest Of Europe Inosine Pranobex Market
7.3.11.1. Market Size and Forecast, By Type
7.3.11.2. Market Size and Forecast, By Application
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Type
7.4.3. Market Size and Forecast, By Application
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. China Inosine Pranobex Market
7.4.6.1. Market Size and Forecast, By Type
7.4.6.2. Market Size and Forecast, By Application
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. Japan Inosine Pranobex Market
7.4.7.1. Market Size and Forecast, By Type
7.4.7.2. Market Size and Forecast, By Application
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. India Inosine Pranobex Market
7.4.8.1. Market Size and Forecast, By Type
7.4.8.2. Market Size and Forecast, By Application
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. South Korea Inosine Pranobex Market
7.4.9.1. Market Size and Forecast, By Type
7.4.9.2. Market Size and Forecast, By Application
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. Australia Inosine Pranobex Market
7.4.10.1. Market Size and Forecast, By Type
7.4.10.2. Market Size and Forecast, By Application
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Inosine Pranobex Market
7.4.11.1. Market Size and Forecast, By Type
7.4.11.2. Market Size and Forecast, By Application
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Type
7.5.3. Market Size and Forecast, By Application
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Inosine Pranobex Market
7.5.6.1. Market Size and Forecast, By Type
7.5.6.2. Market Size and Forecast, By Application
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. South Africa Inosine Pranobex Market
7.5.7.1. Market Size and Forecast, By Type
7.5.7.2. Market Size and Forecast, By Application
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. Saudi Arabia Inosine Pranobex Market
7.5.8.1. Market Size and Forecast, By Type
7.5.8.2. Market Size and Forecast, By Application
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Inosine Pranobex Market
7.5.9.1. Market Size and Forecast, By Type
7.5.9.2. Market Size and Forecast, By Application
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Teva Pharmaceutical Industries Ltd.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Newport Pharmaceuticals Ltd.
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Mylan N.V.
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Adamed Group S.A.
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Sanofi
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Johnson And Johnson
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Pfizer Inc.
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Novartis AG
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Abbott Laboratories
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Merck And Co., Inc.
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments